<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079686</url>
  </required_header>
  <id_info>
    <org_study_id>PosDoc</org_study_id>
    <nct_id>NCT04079686</nct_id>
  </id_info>
  <brief_title>Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty</brief_title>
  <official_title>Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniela Francescato Veiga</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Setting: Translacional Surgery Graduation Program - Universidade Federal de São Paulo and&#xD;
      Hospital das Clínicas Samuel Libânio - Universidade do Vale do Sapucaí. Background: Breast&#xD;
      reduction is one of the most performed plastic surgery procedures. Antibiotics are widely&#xD;
      prescribed, on an empirical basis, to prevent surgical site infections. However, there is a&#xD;
      lack of evidence to support its use. Objective: To compare the influence of the use of&#xD;
      prophylatic antibiotics as a single dose or for 24 hours on surgical site infection rates&#xD;
      following reduction mammaplasty. Methods: Randomized trial of non-inferiority, with two&#xD;
      parallel groups, double blinded. A total of 146 breast hypertrophy patients, with reduction&#xD;
      mammaplasty already scheduled, will be enrolled. Patients will be randomly allocated to group&#xD;
      A, that will receive antibiotics only at the anesthesia induction (n=73), or to group B, that&#xD;
      will receive antibiotics at the anesthesia induction and for 24 hours (n=73). None of the&#xD;
      patients will receive antibiotics after hospital discharge. Patients will be followed-up&#xD;
      weekly, for 30 days, regarding surgical site infection. The Centers for Disease Control and&#xD;
      Prevention criteria will be applied. A statistical analysis of the data will be performed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with surgical site infection (SSI)</measure>
    <time_frame>30 days</time_frame>
    <description>Patients will be monitored for the occurrence of SSI once weekly during the first 30 days following hospital discharge by a single surgeon who is blinded to their treatment group. SSI will be evaluated based on the definition adopted by the Centers for Disease Control and Prevention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Plastic Surgery</condition>
  <condition>Mammaplasty</condition>
  <condition>Anti-bacterial Agents</condition>
  <condition>Prophylaxis</condition>
  <condition>Wound Infection</condition>
  <arm_group>
    <arm_group_label>Cephazolin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive antibiotics (1g cephazolin) intravenously at the anesthestic induction and every 6 hours for 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive antibiotics (cephazolin) only at the anesthesia induction, and sterile saline intravenously every 6 hours for 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephazolin</intervention_name>
    <description>Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.</description>
    <arm_group_label>Cephazolin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sterile saline</intervention_name>
    <description>Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.</description>
    <arm_group_label>Sterile saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 and 60 years of age&#xD;
&#xD;
          -  body mass index (BMI) between 19 and 30 kg/m2&#xD;
&#xD;
          -  breast hypertrophy according to the criteria of Sacchini et al. and Franco and Rebello&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who had previously undergone another surgical procedure of the breast&#xD;
&#xD;
          -  patients who have been diagnosed with a breast pathology&#xD;
&#xD;
          -  smokers&#xD;
&#xD;
          -  patients who had a child or breastfed within the last year&#xD;
&#xD;
          -  patients with uncontrolled comorbidities, such as arterial hypertension or diabetes&#xD;
&#xD;
          -  use of immunosuppressants&#xD;
&#xD;
          -  patients who had any infection during the follow-up period, requiring the use of&#xD;
             antibiotics&#xD;
&#xD;
          -  patients who present any adverse effects due to the antibiotics during the study&#xD;
&#xD;
          -  patients who miss follow-up assessments&#xD;
&#xD;
          -  patients who withdraw their consent at any time&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela F Veiga, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela F Veiga, MD, PhD</last_name>
    <phone>55-11-55764848</phone>
    <phone_ext>3054</phone_ext>
    <email>danielafveiga@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joel Veiga-Filho, MD, PhD</last_name>
    <phone>55-35-34232502</phone>
    <email>veigafilhoj@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clinicas Samuel Libânio, Universidade do Vale do Sapucaí</name>
      <address>
        <city>Pouso Alegre</city>
        <state>MG</state>
        <zip>37550000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela F Veiga, MD, PhD</last_name>
      <phone>55-35-34492199</phone>
      <email>danielafveiga@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Joel Veiga-Filho, MD, PhD</last_name>
      <phone>55-35-34232502</phone>
      <email>veigafilhoj@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joel Veiga-Filho, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331275/pdf/13063_2020_Article_4539.pdf</url>
    <description>Study Protocol</description>
  </link>
  <reference>
    <citation>Veiga DF, da Silva Garcia E, Moreira-Filho JW, de Mattos Andrade EB, Juliano Y, Veiga-Filho J, Ferreira LM. Single dose versus 24 h antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial. Trials. 2020 Jul 2;21(1):605. doi: 10.1186/s13063-020-04539-0.</citation>
    <PMID>32616026</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Daniela Francescato Veiga</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

